Surgical treatment of metastatic melanoma

William S. Fletcher, Rodney Pommier, Sharon Lum, Thea J. Wilmarth

    Research output: Contribution to journalArticle

    59 Citations (Scopus)

    Abstract

    BACKGROUND: The survival of patients with metastatic melanoma is poor. The response rates for chemotherapy and immunotherapy have been low, with no real improvement in survival. We reviewed the results of surgical resection. METHODS: We performed a retrospective review of the medical records of all patients who underwent resection of metastases from melanoma from 1979 to 1994. RESULTS: There were 77 patients (44 men, 33 women, mean age 51 years). Metastases were resected from soft tissue (n = 28), abdominal viscera (n = 22), lung (n = 15), and brain (n = 12). Forty-four patients had complete resections, and 33 had incomplete resections. Sixty-five patients had solitary lesions and 12 had multiple lesions resected. The overall 5-year survival rate was 10%. Patients with solitary lesions had a 5-year survival rate of 12%, compared with 0% for patients with multiple lesions (P = 0.01). Patients with complete resection had a 5-year survival rate of 15%, compared with 4% for patients with incomplete resection (P <0.001). Patients with complete resection of solitary lesions had a 5-year survival of 18%. There was no difference in survival between synchronous and metachronous resection. Gender, primary site, disease-free interval, and metastatic site had no impact on survival rates. CONCLUSIONS: We conclude that patients with metastatic melanoma should be resected for (1) relief of symptoms such as obstruction and bleeding, (2) solitary lesions that can be completely resected, (3) serial lesions that can be completely resected, and (4) selected cases that can be rendered macroscopically free of disease. Surgical resection is superior to any other available therapy for metastatic melanoma.

    Original languageEnglish (US)
    Pages (from-to)413-417
    Number of pages5
    JournalAmerican Journal of Surgery
    Volume175
    Issue number5
    DOIs
    StatePublished - 1998

    Fingerprint

    Melanoma
    Survival Rate
    Therapeutics
    Survival
    Neoplasm Metastasis
    Viscera
    Immunotherapy
    Medical Records
    Hemorrhage
    Drug Therapy
    Lung
    Brain

    ASJC Scopus subject areas

    • Surgery

    Cite this

    Surgical treatment of metastatic melanoma. / Fletcher, William S.; Pommier, Rodney; Lum, Sharon; Wilmarth, Thea J.

    In: American Journal of Surgery, Vol. 175, No. 5, 1998, p. 413-417.

    Research output: Contribution to journalArticle

    Fletcher, William S. ; Pommier, Rodney ; Lum, Sharon ; Wilmarth, Thea J. / Surgical treatment of metastatic melanoma. In: American Journal of Surgery. 1998 ; Vol. 175, No. 5. pp. 413-417.
    @article{311d4f4d9f6a4f79baf1b09e7800178c,
    title = "Surgical treatment of metastatic melanoma",
    abstract = "BACKGROUND: The survival of patients with metastatic melanoma is poor. The response rates for chemotherapy and immunotherapy have been low, with no real improvement in survival. We reviewed the results of surgical resection. METHODS: We performed a retrospective review of the medical records of all patients who underwent resection of metastases from melanoma from 1979 to 1994. RESULTS: There were 77 patients (44 men, 33 women, mean age 51 years). Metastases were resected from soft tissue (n = 28), abdominal viscera (n = 22), lung (n = 15), and brain (n = 12). Forty-four patients had complete resections, and 33 had incomplete resections. Sixty-five patients had solitary lesions and 12 had multiple lesions resected. The overall 5-year survival rate was 10{\%}. Patients with solitary lesions had a 5-year survival rate of 12{\%}, compared with 0{\%} for patients with multiple lesions (P = 0.01). Patients with complete resection had a 5-year survival rate of 15{\%}, compared with 4{\%} for patients with incomplete resection (P <0.001). Patients with complete resection of solitary lesions had a 5-year survival of 18{\%}. There was no difference in survival between synchronous and metachronous resection. Gender, primary site, disease-free interval, and metastatic site had no impact on survival rates. CONCLUSIONS: We conclude that patients with metastatic melanoma should be resected for (1) relief of symptoms such as obstruction and bleeding, (2) solitary lesions that can be completely resected, (3) serial lesions that can be completely resected, and (4) selected cases that can be rendered macroscopically free of disease. Surgical resection is superior to any other available therapy for metastatic melanoma.",
    author = "Fletcher, {William S.} and Rodney Pommier and Sharon Lum and Wilmarth, {Thea J.}",
    year = "1998",
    doi = "10.1016/S0002-9610(98)00041-5",
    language = "English (US)",
    volume = "175",
    pages = "413--417",
    journal = "American Journal of Surgery",
    issn = "0002-9610",
    publisher = "Elsevier Inc.",
    number = "5",

    }

    TY - JOUR

    T1 - Surgical treatment of metastatic melanoma

    AU - Fletcher, William S.

    AU - Pommier, Rodney

    AU - Lum, Sharon

    AU - Wilmarth, Thea J.

    PY - 1998

    Y1 - 1998

    N2 - BACKGROUND: The survival of patients with metastatic melanoma is poor. The response rates for chemotherapy and immunotherapy have been low, with no real improvement in survival. We reviewed the results of surgical resection. METHODS: We performed a retrospective review of the medical records of all patients who underwent resection of metastases from melanoma from 1979 to 1994. RESULTS: There were 77 patients (44 men, 33 women, mean age 51 years). Metastases were resected from soft tissue (n = 28), abdominal viscera (n = 22), lung (n = 15), and brain (n = 12). Forty-four patients had complete resections, and 33 had incomplete resections. Sixty-five patients had solitary lesions and 12 had multiple lesions resected. The overall 5-year survival rate was 10%. Patients with solitary lesions had a 5-year survival rate of 12%, compared with 0% for patients with multiple lesions (P = 0.01). Patients with complete resection had a 5-year survival rate of 15%, compared with 4% for patients with incomplete resection (P <0.001). Patients with complete resection of solitary lesions had a 5-year survival of 18%. There was no difference in survival between synchronous and metachronous resection. Gender, primary site, disease-free interval, and metastatic site had no impact on survival rates. CONCLUSIONS: We conclude that patients with metastatic melanoma should be resected for (1) relief of symptoms such as obstruction and bleeding, (2) solitary lesions that can be completely resected, (3) serial lesions that can be completely resected, and (4) selected cases that can be rendered macroscopically free of disease. Surgical resection is superior to any other available therapy for metastatic melanoma.

    AB - BACKGROUND: The survival of patients with metastatic melanoma is poor. The response rates for chemotherapy and immunotherapy have been low, with no real improvement in survival. We reviewed the results of surgical resection. METHODS: We performed a retrospective review of the medical records of all patients who underwent resection of metastases from melanoma from 1979 to 1994. RESULTS: There were 77 patients (44 men, 33 women, mean age 51 years). Metastases were resected from soft tissue (n = 28), abdominal viscera (n = 22), lung (n = 15), and brain (n = 12). Forty-four patients had complete resections, and 33 had incomplete resections. Sixty-five patients had solitary lesions and 12 had multiple lesions resected. The overall 5-year survival rate was 10%. Patients with solitary lesions had a 5-year survival rate of 12%, compared with 0% for patients with multiple lesions (P = 0.01). Patients with complete resection had a 5-year survival rate of 15%, compared with 4% for patients with incomplete resection (P <0.001). Patients with complete resection of solitary lesions had a 5-year survival of 18%. There was no difference in survival between synchronous and metachronous resection. Gender, primary site, disease-free interval, and metastatic site had no impact on survival rates. CONCLUSIONS: We conclude that patients with metastatic melanoma should be resected for (1) relief of symptoms such as obstruction and bleeding, (2) solitary lesions that can be completely resected, (3) serial lesions that can be completely resected, and (4) selected cases that can be rendered macroscopically free of disease. Surgical resection is superior to any other available therapy for metastatic melanoma.

    UR - http://www.scopus.com/inward/record.url?scp=0031954606&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=0031954606&partnerID=8YFLogxK

    U2 - 10.1016/S0002-9610(98)00041-5

    DO - 10.1016/S0002-9610(98)00041-5

    M3 - Article

    C2 - 9600290

    AN - SCOPUS:0031954606

    VL - 175

    SP - 413

    EP - 417

    JO - American Journal of Surgery

    JF - American Journal of Surgery

    SN - 0002-9610

    IS - 5

    ER -